Cited 0 time in
Geriatric considerations in the diagnosis and management of lower urinary tract dysfunction
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Yong Tae | - |
| dc.date.accessioned | 2022-07-15T20:53:53Z | - |
| dc.date.available | 2022-07-15T20:53:53Z | - |
| dc.date.issued | 2015-10 | - |
| dc.identifier.issn | 1975-8456 | - |
| dc.identifier.issn | 2093-5951 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156274 | - |
| dc.description.abstract | Lower urinary tract dysfunction increases with age. Detrusor overactivity, detrusor underactivity, and detrusor hyperreflexia with impaired contractility are more common in elderly population. The elderly patients usually have cormobidities, comedications, and precipitation factors, which cause or exacerbate urinary symptoms, or aggravate subclinical lower urinary tract dysfunction to overwhelming diseases. Pharmacokinetics and pharmacodynamics changes with age. Older patients may refuse appropriate therapy because they are concerned about adverse effects, and economic burden. Thus strategy for the diagnosis and the management of lower urinary tract dysfunction in elderly might be different from those in young population. The diagnostic evaluation of these patients starts with history taking and non-invasive tests to make a plan to treat patient's symptom. Watchful waiting with lifestyle intervention is a good treatment modality. If pharmacotheraphy is planned, it would be better to start with low dose, then escalate dose. Adverse effects of medications are more common in elderly patients not by old age, but by comorbidity and comedication. First follow up might be in a short period after prescription when adverse effects usually occur. | - |
| dc.format.extent | 5 | - |
| dc.language | 한국어 | - |
| dc.language.iso | KOR | - |
| dc.publisher | 대한의사협회 | - |
| dc.title | Geriatric considerations in the diagnosis and management of lower urinary tract dysfunction | - |
| dc.title.alternative | 노인의 배뇨장애 진단 및 치료 시 유의사항 | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.5124/jkma.2015.58.10.873 | - |
| dc.identifier.scopusid | 2-s2.0-84946097895 | - |
| dc.identifier.bibliographicCitation | Journal of the Korean Medical Association, v.58, no.10, pp 873 - 877 | - |
| dc.citation.title | Journal of the Korean Medical Association | - |
| dc.citation.volume | 58 | - |
| dc.citation.number | 10 | - |
| dc.citation.startPage | 873 | - |
| dc.citation.endPage | 877 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART002040832 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.subject.keywordPlus | alpha adrenergic receptor blocking agent | - |
| dc.subject.keywordPlus | antidepressant agent | - |
| dc.subject.keywordPlus | antihistaminic agent | - |
| dc.subject.keywordPlus | calcium channel blocking agent | - |
| dc.subject.keywordPlus | cholinergic receptor blocking agent | - |
| dc.subject.keywordPlus | corticosteroid | - |
| dc.subject.keywordPlus | dipeptidyl carboxypeptidase inhibitor | - |
| dc.subject.keywordPlus | diuretic agent | - |
| dc.subject.keywordPlus | estrogen | - |
| dc.subject.keywordPlus | lithium | - |
| dc.subject.keywordPlus | neuroleptic agent | - |
| dc.subject.keywordPlus | nonsteroid antiinflammatory agent | - |
| dc.subject.keywordAuthor | Drug therapy | - |
| dc.subject.keywordAuthor | Geriatrics | - |
| dc.subject.keywordAuthor | Lower urinary tract symptoms | - |
| dc.identifier.url | https://synapse.koreamed.org/articles/1043002 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
